Tamoxifen resistance and adjuvant hormone therapy
نویسندگان
چکیده
منابع مشابه
Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III.
Plasma levels of luteinizing hormone, sex hormone binding globulin, and antithrombin III were measured in pre- and postmenopausal breast cancer patients receiving adjuvant combination chemotherapy or combination chemotherapy and long-term tamoxifen therapy. The aim was to determine the estrogen-like effects of tamoxifen. The premenopausal patients had received tamoxifen for between 434 and 2592...
متن کاملWhat Is the Optimum Duration of Tamoxifen Adjuvant Therapy?
Finally, there are fascinating biologic reasons to address this issue further. In essence, our understanding of the mechanism of action of tamoxifen and other hormonal agents is changing. Initial theories suggested these agent were cytostatic and essentially acted by "freezing" cells in the early G1 phase of the cell cycle. Thus, it was logical to hypothesize that it may be necessary to adminis...
متن کاملUnderstanding resistance to tamoxifen in hormone receptor-positive breast cancer.
The selective estrogen receptor (ER) modulator tamoxifen has been used for more than 30 years to treat and, more recently, to prevent breast cancer. Unfortunately, even among patients with ER-positive tumors, the response achieved with tamoxifen treatment is variable. Recent years have seen a sharp increase in the number of studies suggesting that the efficacy and safety of anticancer therapies...
متن کاملNeoadjuvant and Adjuvant Hormone Therapy: How and When?
Context: A significant proportion of patients with prostate cancer (PCa) will experience clinical or biochemical failure after local treatment with radical prostatectomy (RP) or radiotherapy (RT). It is still a matter of debate whether hormone therapy (HT) in either a neoadjuvant or adjuvant setting can offer a survival benefit for these patients. Objective: This review paper discusses how and ...
متن کاملPattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen.
In breast cancer patients receiving adjuvant tamoxifen after unilateral treatment, contralateral breast cancer (CBC) is extremely rare. As a result, only limited data are available on the hormone receptor status of CBCs evolving in tamoxifen-treated patients. The aim of our investigation was to evaluate the pattern of hormone receptor status of CBCs in patients treated with adjuvant tamoxifen a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Breast Cancer Research
سال: 2005
ISSN: 1465-542X
DOI: 10.1186/bcr1223